Gland Pharma Limited (GLAND.NS)
INR 1403.5
(0.25%)
INR 1403.5
(0.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -14.67 Billion INR | 22.96% |
| 2022 | -19.04 Billion INR | -512.2% |
| 2021 | -3.11 Billion INR | 36.1% |
| 2020 | -4.86 Billion INR | -197.78% |
| 2019 | -1.63 Billion INR | 28.85% |
| 2018 | -2.29 Billion INR | 37.17% |
| 2017 | -3.65 Billion INR | 30.57% |
| 2016 | -5.26 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 18.39 Billion INR | 225.36% |
| 2024 Q2 | -25.25 Billion INR | -235.56% |
| 2023 Q3 | 21.44 Billion INR | 1832.56% |
| 2023 FY | -14.67 Billion INR | 22.96% |
| 2023 Q2 | -1.23 Billion INR | -103.28% |
| 2023 Q1 | 37.7 Billion INR | 297.99% |
| 2023 Q4 | -14.67 Billion INR | -168.41% |
| 2022 Q1 | 32.48 Billion INR | 1144.2% |
| 2022 Q2 | -5.29 Billion INR | -116.31% |
| 2022 Q4 | -19.04 Billion INR | -157.8% |
| 2022 FY | -19.04 Billion INR | -512.2% |
| 2022 Q3 | 32.95 Billion INR | 722.12% |
| 2021 Q1 | 30.05 Billion INR | 717.42% |
| 2021 FY | -3.11 Billion INR | 36.1% |
| 2021 Q3 | 29.28 Billion INR | 1197.43% |
| 2021 Q2 | -2.66 Billion INR | -108.88% |
| 2021 Q4 | -3.11 Billion INR | -110.62% |
| 2020 Q4 | -4.86 Billion INR | 0.0% |
| 2020 Q1 | -3.75 Billion INR | -129.86% |
| 2020 FY | -4.86 Billion INR | -197.78% |
| 2019 FY | -1.63 Billion INR | 28.85% |
| 2019 Q4 | -1.63 Billion INR | 0.0% |
| 2019 Q1 | 7.2 Billion INR | 0.0% |
| 2018 FY | -2.29 Billion INR | 37.17% |
| 2017 FY | -3.65 Billion INR | 30.57% |
| 2016 FY | -5.26 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott India Limited | -20.51 Billion INR | 28.47% |
| Cipla Limited | -3.15 Billion INR | -364.972% |
| GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | -2076.597% |
| Kopran Limited | 850.3 Million INR | 1825.582% |
| Marksans Pharma Limited | -4.29 Billion INR | -241.609% |
| NGL Fine-Chem Limited | 307.22 Million INR | 4875.883% |
| Pfizer Limited | -19.52 Billion INR | 24.839% |
| Sanofi India Limited | -3.87 Billion INR | -278.649% |
| SMS Pharmaceuticals Limited | 2.44 Billion INR | 699.942% |
| TTK Healthcare Limited | -7.52 Billion INR | -95.082% |